title: The uniqueness of the Trypanosoma cruzi mitochondrion: opportunities to identify new drug target for the treatment of Chagas disease.
abstract: Trypanosoma cruzi is the causative agent of Chagas' disease, which affects some 8 - 10 million people in the Americas. The only two drugs approved for the etiological treatment of the disease in humans were launched more than 40 years ago and have serious drawbacks. In the present work, we revisit the unique characteristics of T. cruzi mitochondria and mitochondrial metabolism. The possibility of taking advantage of these peculiarities to target new drugs against this parasite is also discussed.
authors: Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brasil.
authors: Paes
authors: P
authors: Lisvane Silva
authors: Brian Suárez
authors: BS
authors: Mantilla
authors: Maria Julia
authors: MJ
authors: Barisón
authors: Carsten
authors: C
authors: Wrenger
authors: Ariel Mariano
authors: AM
authors: Silber
mesh_terms: D000977:Antiparasitic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014355:Chagas Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology / Q000635:transmission; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology / Q000473:pathology*; D058990:Molecular Targeted Therapy; D014349:Trypanosoma cruzi / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure
chemical_list: D000977:Antiparasitic Agents